UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Historical Holders from Q1 2014 to Q3 2025

Symbol
UTHR on Nasdaq
CUSIP
91307C102
Type / Class
Equity / Common Stock
Shares outstanding
44.8M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
40.8M
Holdings value
$17.1B
% of all portfolios
0.022%
Grand Portfolio weight change
-0.002%
Number of holders
677
Number of buys
304
Number of sells
-339
Average Value change %
+0%
Average buys %
+0.008%
Average sells %
-0.005%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
STATE STREET CORP 4.9% $644M 2.2M STATE STREET CORPORATION Dec 31, 2024
WELLINGTON MANAGEMENT GROUP LLP 4.5% -16.7% $593M -$128M 2.03M -17.8% Wellington Management Group LLP Mar 31, 2025

Institutional Holders of UNITED THERAPEUTICS Corp - Common Stock (UTHR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 40.8M $17.1B -$1.06B $419.21 677
2025 Q2 43.9M $12.6B -$128M $287.35 661
2025 Q1 44.4M $13.7B +$61.3M $308.27 659
2024 Q4 43.9M $15.5B +$188M $352.84 663
2024 Q3 43.1M $15.4B -$896M $358.35 617
2024 Q2 45.8M $14.6B +$484M $318.55 559
2024 Q1 44.7M $10.3B +$36.8M $229.72 517
2023 Q4 652K $143M +$8.24M $219.89 7
2023 Q3 43.5M $9.83B -$174M $225.87 496
2023 Q2 44.1M $9.73B -$249M $220.75 459
2023 Q1 44.6M $10B -$12.8M $223.96 491
2022 Q4 44.3M $12.3B +$52.9M $278.09 498
2022 Q3 43.5M $9.1B +$90.8M $209.38 436
2022 Q2 43.3M $10.2B +$122M $235.64 452
2022 Q1 43.4M $7.78B +$131M $179.41 406
2021 Q4 42.6M $9.21B -$255M $216.08 402
2021 Q3 43.5M $8.03B +$131M $184.58 409
2021 Q2 43M $7.71B +$18.7M $179.41 392
2021 Q1 42.2M $7.07B +$72.1M $167.27 380
2020 Q4 43M $6.53B +$196M $151.79 343
2020 Q3 41.5M $4.19B -$27M $101.00 314
2020 Q2 42M $5.08B -$62.9M $121.00 334
2020 Q1 42.3M $4.01B +$197M $94.83 288
2019 Q4 41.1M $3.62B -$14.4M $88.08 306
2019 Q3 40.5M $3.23B -$40M $79.75 286
2019 Q2 40.9M $3.19B -$110M $78.06 305
2019 Q1 42.7M $5B -$6.69M $117.37 361
2018 Q4 42.8M $4.64B -$44.7M $108.90 347
2018 Q3 42.4M $5.41B +$117M $127.88 354
2018 Q2 42.1M $4.76B -$111M $113.15 360
2018 Q1 43.3M $4.85B +$10.7M $112.36 361
2017 Q4 43.1M $6.36B +$198K $147.95 391
2017 Q3 43.7M $5.12B -$332M $117.19 364
2017 Q2 46.3M $6B -$219M $129.73 367
2017 Q1 47.7M $6.46B +$611M $135.38 401
2016 Q4 46.8M $6.71B -$109M $143.43 393
2016 Q3 48.6M $5.73B -$90.5M $118.08 383
2016 Q2 49.3M $5.22B -$126M $105.92 372
2016 Q1 50.6M $5.64B -$78.6M $111.43 390
2015 Q4 49.7M $7.79B -$12M $156.61 372
2015 Q3 50M $6.56B -$69.2M $131.24 360
2015 Q2 50.4M $8.76B -$264M $173.95 378
2015 Q1 52.4M $9.02B +$259M $172.43 365
2014 Q4 50.5M $6.54B -$247M $129.49 328
2014 Q3 52.8M $6.8B +$111M $128.65 318
2014 Q2 52.2M $4.62B -$1.25B $88.49 303
2014 Q1 53.4M $5.02B -$141M $94.03 303